Novo Nordisk (CPSE:NOVO B) Misses The Mark In Phase 3 Heart Drug Trial

• Novo Nordisk (CPSE:NOVO B) reported that its experimental heart drug ziltivekimab did not meet the primary endpoint in the ZEUS phase 3 trial.
• The study did not show a significant reduction in major adverse cardiovascular events compared with placebo.
• The outcome affects Novo Nordisk's plans to expand further into cardiovascular medicine and led to a non-cash impairment charge.

Novo Nordisk is best known for its obesity and diabetes treatments, which remain central to the business. The setback with ziltivekimab comes as large drug makers look for broader cardiometabolic portfolios and seek additional areas of long term growth. For investors, this trial result shifts attention back to how dependent CPSE:NOVO B remains on its established franchises and what else in the late stage pipeline can offset that concentration.

The ZEUS result may prompt a closer look at Novo Nordisk's clinical priorities, including whether resources move toward other cardiometabolic or metabolic programs. Market participants are likely to track any follow up disclosures on the impairment, future study plans for ziltivekimab, and potential adjustments to the broader cardiovascular strategy.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.

We've flagged 4 risks for Novo Nordisk. See which could impact your investment.

The ZEUS outcome removes one potential growth option for Novo Nordisk in a large cardiovascular market, since ziltivekimab did not reduce major adverse cardiovascular events despite clear IL 6 target engagement. That weakens the case for this drug as a near term revenue driver in atherosclerotic cardiovascular disease and chronic kidney disease. For a company working to reduce reliance on obesity and diabetes products, losing a high profile cardiovascular outcomes readout like this matters for how diversified future earnings could become. At the same time, overall safety looked in line with placebo aside from more serious infections, and the company plans to keep the HERMES and ARTEMIS cardiovascular trials running. Those studies focus on heart failure and post heart attack settings, which are different clinical questions and could still shape whether ziltivekimab has any commercially relevant role. For you as an investor, the key takeaway is that ZEUS points to a more cautious base case for this particular IL 6 asset, while Novo Nordisk’s broader cardiometabolic ambition and R&D budget remain in play.

How This Fits Into The Novo Nordisk Narrative

• This result tests the narrative theme that Novo Nordisk can use new product launches in adjacent disease areas to broaden its metabolic and cardiovascular reach beyond obesity and diabetes.
• ZEUS challenges the idea that all late stage pipeline programs will convert scientific rationale into clear clinical benefit, which matters in a narrative that leans on expanding indications and new therapies.
• The specific impact of ZEUS on how investors think about heart failure, post heart attack opportunities and the overall value of the cardiovascular pipeline does not appear fully reflected in narrative discussions that focus mainly on GLP 1 therapies.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The lack of MACE benefit in ZEUS reinforces a wider risk that not all cardiometabolic pipeline bets will generate market ready products, even when biological markers move in the expected direction.
• ⚠️ Higher rates of serious infections with ziltivekimab, even if overall adverse events were similar to placebo, could limit how payers and regulators view the benefit risk profile in any future submissions.
• 🎁 Novo Nordisk’s decision to continue the HERMES and ARTEMIS cardiovascular trials keeps open potential use cases in heart failure and post heart attack care, which are significant markets if future data are supportive.
• 🎁 The company has other growth drivers such as GLP 1 therapies and obesity collaborations, so this non cash impairment charge from ZEUS does not alter its previously communicated adjusted operating profit outlook for 2026.

What To Watch Going Forward

From here, focus on how Novo Nordisk updates the ziltivekimab program once the full ZEUS data set is presented, including any subgroup analyses that might inform a narrower path forward. Watch what the company says about prioritising capital between cardiovascular projects and core GLP 1 expansion, as well as any adjustments to R&D spending. It is also worth tracking competitor efforts from Eli Lilly, AstraZeneca and Novartis in cardiovascular inflammation and heart failure, since that shapes how differentiated Novo Nordisk’s remaining cardiometabolic pipeline might look if HERMES and ARTEMIS deliver positive or neutral outcomes.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com